Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 979 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thrombus; Embolism Clear all
Completed No phase listed Observational Accepts healthy volunteers

Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women

NCT00883272
View directory record Official record
Conditions
Menopause, Thrombophilia
Interventions
DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 6, 2026, 2:44 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03739593
View directory record Official record
Conditions
Macular Edema
Interventions
AR-1105-CF1, AR-1105-CF2
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 6, 2026, 2:44 AM EDT
Completed Phase 2 Interventional Results available

A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery

NCT00398216
View directory record Official record
Conditions
Thrombosis, Hip Replacement
Interventions
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Hartford, Connecticut • Sarasota, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 6, 2026, 2:44 AM EDT
Terminated Phase 3 Interventional

Right to Left Cardiac Shunt Detection

NCT01773252
View directory record Official record
Conditions
Right to Left Shunt, Patent Foramen Ovale, Atrial Septal Defect
Interventions
Flow Detection System
Device
Lead sponsor
Cardiox Corporation
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 6, 2026, 2:44 AM EDT
Not listed Phase 1Phase 2 Interventional

Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis

NCT04833764
View directory record Official record
Conditions
Post-thrombotic Syndrome, Deep Vein Thrombosis Leg
Interventions
Rosuvastatin
Drug
Lead sponsor
Khanh Nguyen
Federal
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 6, 2026, 2:44 AM EDT
Not listed Not applicable Interventional

Safety and Efficacy of Lean Body Weight-based IV Heparin Dosing in Obese/Morbidly Obese Patients

NCT01363193
View directory record Official record
Conditions
Obesity, Morbid Obesity, Venous Thromboembolism, Atrial Fibrillation, Angina, Chest Pain
Interventions
Lean Body Weight-based heparin dose
Drug
Lead sponsor
Nazareth Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 6, 2026, 2:44 AM EDT
Completed Phase 2 Interventional

Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00020189
View directory record Official record
Conditions
Head and Neck Cancer, Thromboembolism
Interventions
acetylsalicylic acid, alvocidib, clopidogrel bisulfate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 6, 2026, 2:44 AM EDT
Completed Phase 3 Interventional

Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation

NCT01006876
View directory record Official record
Conditions
Thromboembolism
Interventions
Coumadin
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 6, 2026, 2:44 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Comparison of Subcutaneous Heparin and Enoxaparin for Deep Venous Thrombosis (DVT) Prophylaxis in Surgical Intensive Care Patients

NCT01325779
View directory record Official record
Conditions
Lower Extremity Deep Venous Thrombosis
Interventions
heparin, enoxaparin
Drug
Lead sponsor
Lisa Louwers
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 6, 2026, 2:44 AM EDT
Not listed Phase 3 Interventional

Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms

NCT00934427
View directory record Official record
Conditions
Raynaud Disease
Interventions
0.9% nitroglycerin in TAM cream, vehicle cream
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Redwood City, California • Farmington, Connecticut • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2010 · Synced Oct 6, 2026, 2:44 AM EDT
Recruiting Phase 2 Interventional

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

NCT04295486
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Aspirin
Drug
Lead sponsor
University of Miami
Other
Eligibility
19 Years and older
Enrollment
5,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 6, 2026, 2:44 AM EDT
Completed Not applicable Interventional

Computerized Decision Support to Increase Detection of Chronic Thromboembolic Pulmonary Hypertension in Patients With Prior Pulmonary Embolism

NCT03729544
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
On-screen computerized decision support alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 6, 2026, 2:44 AM EDT
Completed No phase listed Observational Results available

Tranexamic Acid and Blood Clots in Knee Surgery

NCT02867163
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Tranexamic Acid
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Rio Rancho, New Mexico
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 6, 2026, 2:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered

NCT02969343
View directory record Official record
Conditions
Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism, Patient Fall, Catheter-Associated Infection, Severe Hypoglycemia, Opioid-Related Severe Adverse Drug Event, Hospital Acquired Pressure Ulcer, Adverse Drug Event, Severe Hospital Acquired Delerium, Rapid Response Related to Arrhythmia
Interventions
Patient Safety health information technology
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
21,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 6, 2026, 2:44 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase II Investigation of 99mTc-rBitistatin for Imaging Venous Thrombosis

NCT00808626
View directory record Official record
Conditions
Venous Thrombosis
Interventions
99mTc-rBitistatin
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 6, 2026, 2:44 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients

NCT02412982
View directory record Official record
Conditions
Traumatic Injury, Venous Thromboembolism
Interventions
Enoxaparin 40 mg q12h, Enoxaparin 30 mg q8h
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 6, 2026, 2:44 AM EDT
Enrolling by invitation Phase 4 Interventional

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

NCT03244020
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases, Venous Thromboembolism, Hematoma, Anticoagulant-induced Bleeding
Interventions
Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2,868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 6, 2026, 2:44 AM EDT
Completed Phase 1 Interventional

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

NCT01145859
View directory record Official record
Conditions
Venous Thrombosis, Pediatrics
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 18 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
16
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 6, 2026, 2:44 AM EDT
Completed Phase 3 Interventional Results available

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

NCT04516278
View directory record Official record
Conditions
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
bevacizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Beverly Hills, California • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 6, 2026, 2:44 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

NCT01011374
View directory record Official record
Conditions
Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
Interventions
ranibizumab (Lucentis)
Drug
Lead sponsor
Retina Associates of Cleveland, Inc
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2011 · Synced Oct 6, 2026, 2:44 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

NCT00680186
View directory record Official record
Conditions
Thromboembolism
Interventions
Warfarin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 6, 2026, 2:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World

NCT04276441
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Heart healthy Engagement Program with the Apple Watch Series 5 or later, Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later
Device
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
65 Years and older
Enrollment
34,244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 6, 2026, 2:44 AM EDT
Withdrawn Phase 2 Interventional

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

NCT00916669
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Etoposide, Cisplatin, enoxaparin sodium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
4
States / cities
Boston, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2013 · Synced Oct 6, 2026, 2:44 AM EDT
Terminated Phase 1 Interventional Results available

PET Fibrin Imaging of DVT and PE

NCT04022915
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Interventions
64Cu-FBP8, PET-CT imaging
Drug · Diagnostic Test
Lead sponsor
Peter Caravan
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 6, 2026, 2:44 AM EDT